Mar 02, 2020

Starpharma appoints David McIntyre and Appendix 3X

Starpharma appoints David McIntyre and Appendix 3X

Melbourne, Australia; 2 March 2020: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that Mr David McIntyre has commenced as an independent non-executive director of Starpharma, effective 1 March.

Mr McIntyre’s appointment follows a comprehensive Board renewal and search process. As advised at the Company’s last AGM, Mr Richard Hazleton will be retiring at the 2020 AGM in November, having served 13 years on the Company’s Board. The timing of Mr McIntyre’s appointment enables a smooth transition and handover between directors.

Mr McIntyre’s bio is available via www.starpharma.com

Commenting on his appointment, Mr McIntyre said: “Starpharma has a unique and highly innovative technology underlying its deep portfolio of products. The platform has very significant potential and I am delighted to join the Board at this exciting time in the Company’s development with multiple clinical stage oncology assets and international roll‑out of the VivaGel® products. Having worked in various executive roles within the life‑sciences industry in both the US and Australia for almost 20 years, I recognise the inherent promise of Starpharma’s unique dendrimer technology and I’m impressed by the depth of the portfolio and commercial potential it generates. I look forward to working with the Board and management team to take the Company forward”.

An Appendix 3X Initial Director’s Interest Notice is attached.

Download ASX Announcement: Starpharma appoints David McIntyre and Appendix 3X (pdf file, 256kb)

 This contains certain forward-looking statements.